Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Refractory hypertension: what do we know so far?

Journal of Human Hypertension volume 35, pages 181–183 (2021)Cite this article

Subjects

Refractory hypertension is currently defined as the failure of office blood pressure (BP) control despite the use of five or more antihypertensive drugs including a long-acting thiazide-like diuretic (ideally chlorthalidone) and a mineralocorticoid receptor antagonist (MRA) [1]. Initially considered as an extreme phenotype of resistant hypertension, recent studies have suggested that they present different pathophysiological mechanisms and refractory hypertension may be a new clinical condition [2, 3].

The first point of discussion is the definition of refractory hypertension. Considering that after the diagnosis of resistant hypertension (use of three or more drugs without control of office BP) [4], the use of Ambulatory Blood Pressure Monitoring (ABPM) or Home Blood Pressure Monitoring (HBPM) becomes mandatory in the diagnostic and therapeutic approach of these patients, in whom the office BP has low value [4,5,6], ideally refractory hypertensive patients should also be followed-up with ABPM or HBPM [3]. Thus, the definition of refractory hypertension might be more reliable and compatible with the clinical practice if it would not be based on office BP but on noncontrolled ABPM or HBPM, which has been called true refractory hypertension [7]. Furthermore, it is crucial to assess non-pharmacological and pharmacological adherence, besides clinical characteristics of these patients to exclude false positive diagnosis [7, 8].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Clinical approach of refractory hypertension.

References

  1. Acelajado MC, Pisoni R, Dudenbostel T, Dell’Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens. 2012;14:7–12.

    Article  Google Scholar 

  2. Modolo R, de Faria AP, Almeida A, Moreno H. Resistant or refractory hypertension: are they different? Curr Hypertens Rep. 2014;16:485–92.

    Article  Google Scholar 

  3. Muxfeldt ES, Chedier B, Rodrigues CIS. Resistant and refractory hypertension: two sides of the same disease? J Bras Nephrol. 2019;41:266–74.

    Article  Google Scholar 

  4. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation and management: a scientific statement from the American Heart Association. Hypertension. 2018;72:e53–90.

    Article  CAS  Google Scholar 

  5. Muxfeldt ES, Salles GF. How to use ambulatory blood pressure monitoring in resistant hypertension. Hypertens Res. 2013;36:385–9.

    Article  Google Scholar 

  6. Muxfeldt ES, Barros GS, Viegas BB, Carlos FO, Salles GF. Is home blood pressure monitoring useful in the management of patients with resistant hypertension? Am J Hypertens. 2015;28:190–9.

    Article  Google Scholar 

  7. Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci. 2017;3:pii: e430.

    Google Scholar 

  8. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun D. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66:126–33.

    Article  CAS  Google Scholar 

  9. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.

    Article  Google Scholar 

  10. Pratt-Ubunama MN, Nishizaka MK, Calhoun DA. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. Curr Hypertens Rep. 2005;7:186–92.

    Article  CAS  Google Scholar 

  11. Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63:451–8.

    Article  CAS  Google Scholar 

  12. Modolo R, de Faria AP, Sabbatini AR, Barbaro NR, Ritter AM, Moreno H. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9:397–402.

    Article  Google Scholar 

  13. Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, et al. Prevalence and clinical characteristics of refractory hypertension. J Am Heart Assoc. 2017;6:e007365.

    Article  Google Scholar 

  14. Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Morales CEN, Calhoun DA, et al. Prevalence of refractory hypertension in the United States from1999 to 2014. J Hypertens. 2019;37:1797–804.

    Article  CAS  Google Scholar 

  15. Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, et al. Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes. Hypertension. 2018;72:343–9.

    Article  CAS  Google Scholar 

  16. Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res. 2019;124:1061–70.

    Article  CAS  Google Scholar 

  17. Siddiqui M, Judd EK, Oparil S, Calhoun DA. White coat effect is uncommon in patients with refractory hypertension. Hypertension 2017;70:645–51.

    Article  CAS  Google Scholar 

  18. Cuspidi C, Tadic M, Grassi G. Refractory hypertension focus on nighttime blood pressure and nondipping. J Clin Hypertens. 2018;20:447–9.

    Article  Google Scholar 

  19. Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2008;51:69–76.

    Article  CAS  Google Scholar 

  20. Parasiliti-Caprino M, Lopez C, Prencipe N, Lucatello B, Settanni F, Giraudo G et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens. 2020. https://doi.org/10.1097/HJH.0000000000002441.

  21. Martínez-García MA, Navarro-Soriano C, Torres G, Barbé F, Caballero-Eraso C, Lloberes P, et al. Beyond resistant hypertension. Hypertension. 2018;72:618–24.

    Article  Google Scholar 

  22. Navarro-Soriano C, Martínez-García MA, Torres G, Barbé F, Caballero-Eraso C, Lloberes P, et al. Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial. J Hypertens. 2019;37:1269–75.

    Article  CAS  Google Scholar 

  23. Siddiqui M, Judd EK, Dudenbostel T, Gupta P, Tomaszewski M, Patel P, et al. Antihypertensive medication adherence and confirmation of true refractory hypertension. Hypertension. 2020;75:510–5.

    Article  CAS  Google Scholar 

  24. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al and British Hypertension Society’s PSG. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.

  25. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e484–594.

    PubMed  Google Scholar 

Download references

Funding

This study was supported by research grants from the Conselho Brasileiro de Desenvolvimento Científico e Tecnológico (CNPq, Distrito Federal, Brazil). The sponsors have no role in in preparation, review and approval of the paper.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hospital Universitário Clementino Fraga Filho, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

    Elizabeth Silaid Muxfeldt

  2. Department of Internal Medicine, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

    Bernardo Chedier

Authors
  1. Elizabeth Silaid Muxfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernardo Chedier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Silaid Muxfeldt.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muxfeldt, E.S., Chedier, B. Refractory hypertension: what do we know so far?. J Hum Hypertens 35, 181–183 (2021). https://doi.org/10.1038/s41371-020-00409-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-020-00409-z

Search

Advanced search

Quick links